Browse EX-10 agreements

2025 Executive Employment Agreement

This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of signing on May 3, 2025 with an effective date of May 1, 2025 (the “Effective Date”), by and between Alternative Ballistics Corporation, a Nevada corporation (together with its successors and assigns, the “Company”), and Vanessa Luna (“Executive”). This agreement is made new for the calendar year 2025 and supersedes all prior agreements.

RECITALS

WHEREAS, the Company and Executive entered into that certain Executive Employment Agreement, dated December 1, 2021 and Company and Executive later amended and restated the Agreement as of August 23, 2024 (the “Prior Agreement”). This new agreement will immediately take effect and supersede the Prior Agreements in its entirety as set forth in this Agreement; and

WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company, as the Company’s Executive Vice President.

…

** **

Exhibit 10.31

** **

** **

ALTERNATIVE BALLISTICS CORPORATION

** **

2021 OMNIBUS EQUITY COMPENSATION PLAN

TABLE OF CONTENTS

ARTICLE I	GENERAL PROVISIONS	3
ARTICLE II	DEFINITIONS	3
ARTICLE III	ADMINISTRATION	8
ARTICLE IV	INCENTIVE STOCK OPTIONS	12
ARTICLE V	NONQUALIFIED STOCK OPTIONS	13

…

OMNIBUS AMENDMENT TO BRIDGE LOAN DOCUMENTS

This Omnibus Amendment (the “Amendment”) is entered into as of July 22, 2025, by and among Alternative Ballistics Corporation, a Nevada corporation (the “Company”), and Solyco CAC LLC, a Michigan limited liability company (the “Investor”).

RECITALS

WHEREAS, the Company and the Investor are parties to that certain Subscription Agreement, Convertible Note, and Warrant Agreement, each dated August 2, 2024, together with all related documents (collectively, the “Transaction Documents”);

WHEREAS, the parties desire to amend certain terms of the Transaction Documents as set forth herein.

AMENDMENT

…

---

EXHIBIT 10.8

EUROSPAC ACQUISITION CORP.

c/o Dr. Tasos Aslidis 11 Canterbury Lane

Watchung, NJ 07069

September 1, 2026

EuroSPAC Acquisition Sponsor LLC c/o Dr. Tasos Aslidis

11 Canterbury Lane

Watchung, NJ 07069

RE: Securities Subscription Agreement

Ladies and Gentlemen:

EuroSPAC Acquisition Corp., a Cayman Islands exempted company (the “Company”), is pleased to accept the offer EuroSPAC Acquisition Sponsor LLC, a Delaware limited liability company, (the “Subscriber” or “you”) has made to subscribe for 6,181,250 Class B ordinary shares, US$0.0001 par value per share of the Company (the “Shares”) (the “Class B Ordinary Shares”), up to 806,250 of which are subject to complete or partial forfeiture by you if the underwriters of the Company’s initial public offering (“IPO”) of units (“Units”) do not fully exercise their over-allotment option (the “Over-allotment Option”). For the purposes of this Agreement, references to “Ordinary Shares” are to, collectively, the Class B Ordinary Shares and the Company’s Class A ordinary share

…

---

EXHIBIT 10.7

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

PROMISSORY NOTE

Principal Amount: Up to $300,000	Dated as of September 1, 2026
	Watchung, New Jersey

…

** **

APEX TREASURY CORP II

2035 Regatta Drive

Vero Beach, Florida 32963

September 4, 2026

Apex Treasury II Sponsor LLC

2035 Regatta Drive

Vero Beach, Florida 32963

RE: Securities Subscription Agreement

Ladies and Gentlemen:

Apex Treasury Corp II, a Cayman Islands exempted company (the “Company”, “we” or “us”), is pleased to accept the offer made by Apex Treasury II Sponsor LLC, a Delaware limited liability company (“Subscriber” or “you”), to purchase 9,583,333 Class B ordinary shares of the Company, of $0.0001 par value per share (the “Shares”), up to 1,250,000 of which are subject to surrender and cancellation by you to the extent that the underwriters of the initial public offering (“IPO”) of the Company’s units, each comprised of one Class A ordinary share and one, or a portion of one, warrant to purchase one Class A ordinary share (“Units”), do not fully exercise their option to purchase additional Units to cover over-allotments, if any (the “Over-allotment Option”). The terms of the sale by the Company of the Shares to Subscriber,

…

** **

THIS INITIAL PUBLIC OFFERING PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

PROMISSORY NOTE

** **

Principal Amount: $300,000	Effective as of August 31, 2026

** **

…

CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN REDACTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

EXCLUSIVE LICENSE AGREEMENT

by and between

BAMBUSA THERAPEUTICS, INC.

and

BIOTHEUS INC.

---

TABLE OF CONTENTS

1.							DEFINITIONS	2
2.							LICENSES	19
3.							NON-COMPETE	27
4.							BIOTHEUS DEVELOPMENT ACTIVITIES	28
5.							DEVELOPMENT AND COMMERCIALIZATION	28
6.							JOINT STEERING COMMITTEE	33

…

BAMBUSA THERAPEUTICS, INC.

INDEMNIFICATION AGREEMENT

This Indemnification Agreement (this “Agreement”) is dated as of [        ], and is between Bambusa Therapeutics, Inc., a Delaware corporation (the “Company”), and [        ] (“Indemnitee”).

RECITALS

A.Indemnitee’s service to the Company substantially benefits the Company.

B.Individuals are reluctant to serve as directors or officers of corporations or in certain other capacities unless they are provided with adequate protection through insurance or indemnification against the risks of claims and actions against them arising out of such service.

C.Indemnitee does not regard the protection currently provided by applicable law, the Company’s governing documents and any insurance as adequate under the present circumstances, and Indemnitee may not be willing to serve as a director or officer without additional protection.

…

Execution Version

CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN REDACTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

RESEARCH COLLABORATION AND OPTION AGREEMENT

This RESEARCH COLLABORATION AND OPTION AGREEMENT (this “Agreement”), effective as of the 12thday of April, 2024 (the “Effective Date”) is made by and between Bambusa Therapeutics, Inc. (“Bambusa”), a corporation organized and existing under the laws of the State of Delaware and having a place of business at National Registered Agents, Inc., 1209 Orange Street, in the city of Wilmington, county of New Castle, State of Delaware, the United States, and Biotheus Inc. (in Chinese: _______________) (“Biotheus” and, together with Bambusa, the “Parties”), a limited liability company organized and existing under the laws of People’s Republic of China, with offices at Unit 10-B, Building 4, No. 1 Keji 7th Road, Tangjiawan Town, Xiangzhou District, Zhuhai City, Guangdong Province, the People’s Repu

…

BAMBUSA THERAPEUTICS, INC.

2024 STOCK PLAN

AMENDED AND RESTATED: October 5, 2026

1.Purposes of the Plan.The purposes of this 2024 Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees and Consultants, and to promote the success of the Company’s business. Options granted under the Plan may be Incentive Stock Options or Nonstatutory Stock Options, as determined by the Administrator at the time of grant of an Option and subject to the applicable provisions of Section 422 of the Code and the regulations promulgated thereunder. Restricted Stock and Other Awards may also be granted under the Plan.

2.Definitions.As used herein, the following definitions shall apply:

(a)“Administrator”means the Board or a Committee.

(b)“Affiliate”means (i) an entity other than a Subsidiary which, together with the Company, is under common control of a third person or entity and (ii) an entity other than a Subsidiary in which the Company and /or one or more Subsidiaries own a controlling interest.

…

BAMBUSA THERAPEUTICS, INC.

EMPLOYEE INCENTIVE COMPENSATION PLAN

1.Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives.

2.Definitions.

2.1“Actual Award” means as to any Performance Period, the actual award (if any) payable to a Participant for the Performance Period, subject to the authority of the Administrator (as defined in Section 3) under Section 4.4.

2.2“Administrator” has the meaning ascribed to it under Section 3.1.

2.3“Affiliate” means any corporation or other entity (including, but not limited to, partnerships and joint ventures) that, from time to time and at the time of any determination, directly or indirectly, is in control of or is controlled by the Company.

2.4“Board” means the Board of Directors of the Company.

…